Matrix metalloproteinase 9 in human plasma has 96% specificity and 56% sensitivity for gastric cancer screening

International Journal of Clinical Oncology

Volumn 1, Issue 1, 1996, Pages 39-43

  Torii, Akihito ^a   Kodera, Yasuhiro ^a   Uesaka, Katsuhiko ^a   Hirai, Takashi ^a   Yasui, Kenzo ^a   Morimoto, Takeshi ^a   Yamamura, Yoshitaka ^a   Kato, Tomoyuki ^a   Hayakawa, Taro ^b   Fujimoto, Noboru ^c   Kito, Tsuyoshi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

^c FUJI CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

Diagnosis; Gastric cancer; Matrix metalloproteinase

Indexed keywords

EID: 0008128601     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02347267     Document Type: Article

References (17)

1. Ballin M, Gomez DE, Sinha CC, Thorgeirsson UP. Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype. Biochem Biophys Res Commun 1988;154:832-838.
2. Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989;264:17213-17222.
3. Yamagata S, Tanaka R, Ito Y, Shimizu S. Gelatinases of murine metastatic tumor cells. Biochem Biophys Res Commun 1989;158:228-234.
4. Mackay AR, Hartzier JL, Pelina MD, Thorgeirsson UP. Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen. J Biol Chem 1990;265:21929-21934.
5. Moll UM, Youngleib GL, Rosinski KB, Quigley JP.Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme form HT1080 tumor cells. Cancer Res 1990;50:6162-6170.
6. Tryggvason K, Höyhtyä M, Pyke C.Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993;24:209-218.
7. Bergmann U, Michaelis J, Oberhoff R, Knauper V, Beckmann R, Tschesche H. Enzyme linked immunosorbent assay (ELISA) for the quantitative determination of human leukocyte collagenase and gelatinase. J Clin Chem Clin Biochem 1989;27:351-359.
8. Zucker S, Lysik RM, Gulfinkel M, Zarrabi MH, Stetler-Stevenson W, Liotta LA, Brikedal-Hansen H, Mann W. Immunoassay of type IV collagenase/gelatinase (MMP-2) in human plasma. J Immunol Methods 1992;148:189-198.
9. Zucker S, Lysik RM, Zarrabi MH, Moll U. Mr 92,000 type IV collagenase is increased in plasma of patients with colon and breast cancer. Cancer Res 1993;53:140-146.
10. Nishi M, Omori Y, Miwa K (eds). Japanese classification of gastric carcinoma, ed. 1. Tokyo: Kanehara & Co. Ltd., 1995.
11. Fujimoto N, Hosokawa N, Iwata K, Shinya T, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for inactive precursor and complexed form of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin Chim Acta 1994;231:79-88.
12. Kodera Y, Isobe K, Yamauchi M, Satta T, Hasegawa T, Oikawa S, Kondoh K, Akiyama S, Itoh K, Nakashima I, Takagi H. Expression of carcinoembryonic antigen (CEA) and nonspecific crossreacting antigen (NCA) in gastrointesitinal cancer; the correlation with degree of differentiation. Br J Cancer 1993;68:130-136.
13. Wobbes T, Thomas CMG, Segers MFG, Nagengast FM. Evaluation of seven tumor markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer 1992;69:2036-2041.
14. Kikuchi S, Wada O, Miki K, Nakajima T, Nishi T, Kobayashi O, Inaba Y. Serum pepsinogen as a new marker for gastric carcinoma among young adults. Cancer 1994;73:2695-2702.
15. Brito MJ, Williams GT, Thompson H, Filipe MI. Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa. Gut 1994;35:1697-1700.
16. Harada H, Tsukada Y, Karasawa Y. Evaluation of tumor-associated antigen (2H6 antigen) in detecting early stage of gastric cancer. Clin Chim Acta 1994;228:101-112.
17. Okazaki I, Matsuyama S, Suzuki F, Maruyama K, Maruta A, Kubochi K, Yoshino K, Kobayashi Y, Abe O, Tsuchiya M. Endogenous urinary 3-hydroxyproline has 96% specificity and 44% sensitivity for cancer screening. J Lab Clin Med 1992;120:908-920.